EUVIMEDEUVIMED entdecken
Crossref

Photodynamic therapy of onychomycosis: modern photosensitizers and clinical efficacy (a review)

Valentina V. Glushak, Ivan S. Maximov, Uliana A. Botova

Russian Journal of Skin and Venereal Diseases · 10.09.2026 · 29 (5) · 580-588

DOI: 10.17816/dv707811 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Russian Journal of Skin and Venereal Diseases, online erschienen am 10.09.2026. Verfasst von Valentina V. Glushak und 2 weiteren Autor:innen. Die Arbeit nennt 39 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Onychomycosis is a widespread fungal disease of the nail apparatus characterized by a high relapse rate with standard therapy methods. The growing resistance of dermatophytes, including Trichophyton indotineae, underscores the need to search for alternative therapeutic approaches. A search of sources was conducted in the PubMed/MEDLINE and Russian Science Citation Index databases for the period 2000–2025, and current data on the efficacy and safety of photodynamic therapy in onychomycosis were analyzed, with a focus on photosensitizer characteristics and procedure parameters, using the keywords “photodynamic therapy,” “onychomycosis,” “photosensitizer,” “5-ALA,” “methylene blue,” “toluidine blue,” “chlorophyllic and chlorine-like compounds,” “hypericin,” “diode laser,” “systemic antifungals.” Randomized controlled trials, cohort studies, case series, and experimental studies were included in the review. The review considers five main classes of photosensitizers used in photodynamic therapy of onychomycosis: methylene blue, toluidine blue, 5-aminolevulinic acid/methyl aminolevulinate, hypericin, and chlorophyllic/chlorin-like compounds. In a randomized study, photodynamic therapy with methylene blue demonstrated clinical cure in 90% of patients versus 63% with fluconazole (p 0.002). The combination of toluidine blue with 8% ciclopirox provided 100% mycological cure in patients with diabetes mellitus. Photodynamic therapy with methyl aminolevulinate in a multicenter randomized controlled trial showed clinical cure in 18.18% and mycological cure in 31.82% of patients; in nondystrophic onychomycosis, the rates reached 53.85% and 41.56%, respectively. Thus, photodynamic therapy represents a promising alternative and adjunct to standard onychomycosis therapy, with a minimal risk of systemic adverse effects and the absence of resistance formation. To introduce photodynamic therapy into clinical practice, standardization of protocols is required, including wavelength parameters, irradiation dose, and frequency of procedures, as well as preliminary preparation of the nail plate—mechanical treatment and removal of affected areas to ensure adequate penetration of the photosensitizer.

Zitieren

APA

Glushak, V. V., Maximov, I. S., & Botova, U. A. (2026). Photodynamic therapy of onychomycosis: modern photosensitizers and clinical efficacy (a review). Russian Journal of Skin and Venereal Diseases, 29(5), 580-588. https://doi.org/10.17816/dv707811

Vancouver

Glushak VV, Maximov IS, Botova UA. Photodynamic therapy of onychomycosis: modern photosensitizers and clinical efficacy (a review). Russian Journal of Skin and Venereal Diseases. 2026;29(5):580-588. doi:10.17816/dv707811

BibTeX
@article{Glushak2026,
  author = {Glushak, Valentina V. and Maximov, Ivan S. and Botova, Uliana A.},
  title = {Photodynamic therapy of onychomycosis: modern photosensitizers and clinical efficacy (a review)},
  journal = {Russian Journal of Skin and Venereal Diseases},
  year = {2026},
  volume = {29},
  number = {5},
  pages = {580--588},
  doi = {10.17816/dv707811}
}
Kostenlos starten →